logo-loader

Motif Bio: Latest data burnishes the credentials of new antibiotic

Published: 02:43 05 Sep 2018 EDT

researcher using microscope
Much of the latest data comes from two phase III clinical trials carried out by Motif

Data will be presented at a conference that suggests Motif Bio Plc’s (LON:MTFB) next-generation antibiotic has a number of advantages over the current crop of drugs designed to combat infection.

A review of the two phase III studies carried out on iclaprim showed there were fewer adverse events among diabetic patients taking the drug than those on the standard of care, a treatment called Vancomycin.

Drilling down, the statistical read-out showed no patients in the iclaprim group developed kidney injury, compared with three on Vancomycin.

Additionally, only 3.6% of the iclaprim group had to be taken off the drug compared with 10% receiving the standard of care.

Separately, surveillance data from work performed in the lab has confirmed iclaprim has the potential to work against a wide variety of Gram-positive bacteria, including drug-resistant strains.

Need for new antibiotics

"Given the worldwide crisis in antibiotic resistance, there remains a major need for new antibiotic treatments,” said David Huang, Motif’s chief medical officer.

“We have shown comprehensive data indicating that iclaprim has potent activity against a wide variety of Gram-positive bacteria, including MRSA that cause severe skin infections.”

The latest statistical update will be presented later Wednesday at an industry conference being held in Lisbon.

After successfully negotiating two phase III clinical trials a new drug submission has been made to the US Food & Drug Administration, which will come back with a decision on iclaprim in February next year.

Initially, the antibiotic will be used to treat acute bacterial skin and skin structure infections.

Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

48 minutes ago